StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report published on Tuesday. The brokerage issued a sell rating on the medical technology company’s stock.
Several other research analysts have also weighed in on BIOL. Benchmark reissued a “speculative buy” rating and set a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd. Ascendiant Capital Markets dropped their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.
Get Our Latest Stock Analysis on BIOLASE
BIOLASE Stock Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its position in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.79% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Read More
- Five stocks we like better than BIOLASE
- Energy and Oil Stocks Explained
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- NYSE Stocks Give Investors a Variety of Quality Options
- Top-Performing Non-Leveraged ETFs This Year
- How to Evaluate a Stock Before Buying
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.
